The DOI matches its Crossref record; 136 of the 136 references it cites were found in a registry or an index.
2025 Focused Update of the 2019 ESC/EAS Guidelines for the management of dyslipidaemias
Open accessAbstract
1. Preamble 4361 2. Introduction 4363 3. Estimation of total cardiovascular risk and implications for dyslipidaemia management 4363 4. New low-density lipoprotein cholesterol-lowering therapies 4367 5. Combination of lipid-lowering therapies during index hospitalization for acute coronary syndromes 4369 6. Lipoprotein(a) 4370 7. Hypertriglyceridaemia 4371 8. Primary prevention in people with human immunodeficiency virus infection 4372 9. Patients with cancer at high or very high chemotherapy-related cardiovascular toxicity risk 4373 10. Dietary supplements 4373 11. Evidence tables 4374 12. Data availability statement 4374 13. Author information 4374 14. Appendix 4374 15. References 4375 Recommendation Table 1 — Recommendations for cardiovascular risk estimation in persons without known cardiovascular disease (see also Supplementary data online, Evidence Table 1) 4367 Recommendation Table 2 — Recommendations for pharmacological low-density lipoprotein cholesterol lowering (see also Supplementary data online, Evidence Table 2) 4369 Recommendation Table 3 — Recommendations for lipid-lowering therapy in patients with acute coronary syndromes (see also Supplementary data online, Evidence Table 3) 4370 Recommendation Table 4 — Recommendations for measurement of lipoprotein(a) (see also Supplementary data online, Evidence Table 4) 4370 Recommendation Table 5 — Recommendations for drug treatment of patients with hypertriglyceridaemia (see also Supplementary data online, Evidence Table 5) 4372 Recommendation Table 6 — Recommendations for statin therapy in primary prevention for people with human immunodeficiency virus infection (see also Supplementary data online, Evidence Table 6) 4373 Recommendation Table 7 — Recommendations for statin therapy in patients receiving cancer therapy (see also Supplementary data online, Evidence Table 7) 4373 Recommendation Table 8 — Recommendations for dietary supplements (see also Supplementary data online, Evidence Table 8) 4374 Table 1 Classes of recommendations 4362 Table 2 Levels of evidence 4362 Table 3 Cardiovascular risk categories 4364 Table 4 Intervention strategies as a function of total cardiovascular risk and untreated low-density lipoprotein cholesterol levels 4365 Figure 1 Treatment goals for low-density lipoprotein cholesterol across categories of total cardiovascular risk 4366 Figure 2 Average reduction in low-density lipoprotein cholesterol levels with different pharmacological therapies with proven cardiovascular benefits 4368 Figure 3 Association between Lp(a) levels and lifetime risk of major cardiovascular events 4371 Acute coronary syndromes Alanine aminotransferase Apolipoprotein B Apolipoprotein C-III Antiretroviral therapy Atherosclerotic cardiovascular disease Aspartate aminotransferase Aortic valve stenosis Coronary artery calcium Confidence interval Computed tomography Cardiovascular Cardiovascular disease Docosahexaenoic acid European Atherosclerosis Society European Medicines Agency Eicosapentaenoic acid European Society of Cardiology Familial chylomicronaemia syndrome US Food and Drug Administration Familial hypercholesterolaemia High-density lipoprotein cholesterol Human immunodeficiency virus Hazard ratio Low-density lipoprotein cholesterol Lipoprotein(a) Left ventricular ejection fraction Monoclonal antibody Major adverse cardiovascular event(s) Myocardial infarction Percutaneous coronary intervention Proprotein convertase subtilisin/kexin type 9 Peroxisome proliferator-activated receptor n-3 polyunsaturated fatty acid People with HIV Systematic Coronary Risk Evaluation 2 Systematic Coronary Risk Evaluation 2-Older Persons Total cholesterol Type 1 diabetes mellitus Type 2 diabetes mellitus Upper limit of normal Guidelines evaluate and summarize available evidence with the aim of assisting health professionals in proposing the best diagnostic or therapeutic approach for an individual patient with a given condition. The European Society of Cardiology (ESC) Guidelines are intended for use by health professionals but do not override their individual responsibility to make appropriate and accurate decisions in consideration of each patient's health condition and in consultation with the patient or the patient's caregiver where appropriate and/or necessary aiming at shared care decisions. It is also the health professional's responsibility to verify the rules and regulations applicable in each country to drugs and devices at the time of prescription and to respect the ethical rules of their profession. The ESC Guidelines represent the official position of the ESC on a given topic. Guideline topics are selected for updating after annual expert review of new evidence conducted by the ESC Clinical Practice Guidelines (CPG) Committee. ESC Policies and Procedures for formulating and issuing the ESC Guidelines can be found on the ESC website (https://www.escardio.org/Guidelines/Clinical-Practice-Guidelines/Guidelines-development/Writing-ESC-Guidelines). Interim
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Importantly, the guidelines highlight that variability in LDL-C lowering is observed across all treatment options, likely reflecting differences in background LLT regimens [45].”
From Systematic literature review on the real-world effectiveness and safety of bempedoic acid (2026) · cites this paper as [45]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“In line with this, they emphasize the importance of monitoring LDL-C response 4 to 6 weeks after initiation or intensification and making timely treatment adjustments to achieve recommended targets [45].”
From Systematic literature review on the real-world effectiveness and safety of bempedoic acid (2026) · cites this paper as [45]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The recent ESC/EAS 2025 Focused Update Guideline [9] emphasizes that elevated TG and TRLs contribute independently to cardiovascular risk, even in patients achieving LDL-C targets.”
From Targeting triglycerides for cardiovascular risk reduction (2026) · cites this paper as [9]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The recent 2025 ESC/EAS Focused Update confirms this guidance, emphasizing the persistent role of statins as the cornerstone therapy for cardiovascular risk reduction in the presence of elevated TG, not only by targeting LDL-C but also by modulating TRLs and reducing the atherogenic potential of the lipid profile [9].”
From Targeting triglycerides for cardiovascular risk reduction (2026) · cites this paper as [9]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“The recommendations position bempedoic acid alongside other established LLTs with demonstrated cardiovascular-risk reduction such as statins, ezetimibe, and PCSK9i.”
From Systematic literature review on the real-world effectiveness and safety of bempedoic acid (2026) · cites this paper as [45]
The cited source says what the claim attributes to it.
In the citing paper
“Guidelines also recommend that the choice of treatment should not only be made based on the magnitude of additional LDL-C lowering needed, but also patient preference, treatment availability, and cost [45].”
From Systematic literature review on the real-world effectiveness and safety of bempedoic acid (2026) · cites this paper as [45]
The cited source says what the claim attributes to it.
In the citing paper
“The 2025 ESC/EAS guidelines for the management of dyslipidemia provide new recommendations for bempedoic acid in both patients unable to take statins and as an adjunct to maximally tolerated statin therapy, with or without ezetimibe, including use in high- and very high-risk patients [45].”
From Systematic literature review on the real-world effectiveness and safety of bempedoic acid (2026) · cites this paper as [45]
The cited source says what the claim attributes to it.
In the citing paper
“the 2025 ESC/EAS Focused Update [9] emphasizes that consistent cardiovascular benefit has not been demonstrated in the overall population, and fibrate therapy should therefore be reserved for carefully selected patients with persistent hypertriglyceridaemia or features of atherogenic dyslipidemia despite optimal LDL-C lowering”
From Targeting triglycerides for cardiovascular risk reduction (2026) · cites this paper as [9]
The cited source says what the claim attributes to it.
In the citing paper
“Overall, the joint guideline recognizes TG/TRL-mediated risk as a modifiable component of residual cardiovascular risk, addressed pragmatically through non–HDL-C/apoB targets and selective TG-lowering therapies integrated with intensive LDL-C reduction, with non-fasting testing as the default approach.”
From Targeting triglycerides for cardiovascular risk reduction (2026) · cites this paper as [9]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Mach, F., Baigent, C., Catapano, A. L., Koskinas, K. C., Casula, M., Badimon, L., Chapman, M. J., De Backer, G. G., Delgado, V., Ference, B. A., et al. (2020) · European Heart Journal · doi:10.1093/eurheartj/ehz455 · Cited by 8,961
Self-citationCholesterol Treatment Trialists' (CTT) Collaboration (2010) · The Lancet · doi:10.1016/s0140-6736(10)61350-5 · Cited by 6,550
2021 ESC Guidelines on cardiovascular disease prevention in clinical practice
Visseren, F. L. J., Mach, F., Smulders, Y. M., Carballo, D., Koskinas, K. C., Bäck, M., Benetos, A., Biffi, A., Boavida, J.-M., Capodanno, D., et al. (2021) · European Heart Journal · doi:10.1093/eurheartj/ehab484 · Cited by 6,485
Self-citation2023 ESC Guidelines for the management of acute coronary syndromes
Byrne, R. A., Rossello, X., Coughlan, J. J., Barbato, E., Berry, C., Chieffo, A., Claeys, M. J., Dan, G.-A., Dweck, M. R., Galbraith, M., et al. (2023) · European Heart Journal · doi:10.1093/eurheartj/ehad191 · Cited by 5,333
Self-citationEzetimibe Added to Statin Therapy after Acute Coronary Syndromes
Cannon, C. P., Blazing, M. A., Giugliano, R. P., McCagg, A., White, J. A., Theroux, P., Darius, H., Lewis, B. S., Ophuis, T. O., Jukema, J. W., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1410489 · Cited by 4,487
Ference, B. A., Ginsberg, H. N., Graham, I., Ray, K. K., Packard, C. J., Bruckert, E., Hegele, R. A., Krauss, R. M., Raal, F. J., Schunkert, H., et al. (2017) · European Heart Journal · doi:10.1093/eurheartj/ehx144 · Cited by 3,962
Self-citation2024 ESC Guidelines for the management of chronic coronary syndromes
Vrints, C. J., Andreotti, F., Koskinas, K. C., Rosselló, X., Adamo, M., Ainslie, J., BANNING, A. P., Budaj, A., Buechel, R. R., Chiariello, G. A., et al. (2024) · European Heart Journal · doi:10.1093/eurheartj/ehae177 · Cited by 3,521
Self-citationLyon, A. R., López‐Fernández, T., Couch, L. S., Asteggiano, R., Aznar, M. C., Bergler-Klein, J. K., Boriani, G., Cardinale, D. M., Córdoba, R., Cosyns, B., et al. (2022) · European Heart Journal · doi:10.1093/eurheartj/ehac244 · Cited by 3,457
Self-citationCardiovascular Risk Reduction with Icosapent Ethyl for Hypertriglyceridemia
Bhatt, D. L., Steg, P. G., Miller, M., Brinton, E. A., Jacobson, T. A., Ketchum, S. B., Doyle, R. T., Juliano, R. A., Jiao, L., Granowitz, C., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1812792 · Cited by 3,317
Cited by
Sorted by citations
Items 501–600 of 817
Parada-Barcia, J. A., Pérez, A. R., Eirós-Bachiller, R., Chaparro‐Muñoz, M., Rodríguez-Palomares, J. F., Fernández‐Golfín, C., & Barreiro‐Pérez, M. (2026) · Revista Española de Cardiología (English Edition) · doi:10.1016/j.rec.2026.06.015
Polygenic Prediction of Non-goal Response to Statin Therapy
Liou, L., García‐González, J., Wu, H. M., Namba, S., Vaura, F. C., Okada, Y., Kovacic, J. C., & O’Reilly, P. F. (2026) · Circulation Genomic and Precision Medicine · doi:10.1161/circgen.125.005666
Den nächsten Schlaganfall verhindern
Sander, D. (2026) · MMW - Fortschritte der Medizin · doi:10.1007/s15006-026-5952-5
Federated deep learning for privacy-preserving cardiovascular disease risk prediction
Mo, H., Smits, D., Birhanu, M. A., Leening, M. J. G., Bos, D., van der Harst, P., & Bron, E. E. (2026) · Frontiers in Applied Mathematics and Statistics · doi:10.3389/fams.2026.1923866
Self-citationTong, M., Chen, C., & Pan, Y. (2026) · Medicine · doi:10.1097/md.0000000000049631
CDA-AMC (2026) · Canadian Journal of Health Technologies · doi:10.51731/cjht.2026.1472
Giannakopoulou, S., Chrysohoou, C. A., Antonopoulou, S., Barkas, F., Liberopoulos, E. N., Sfikakis, P. P., Pitsavos, C. E., Tsioufis, C., & Panagiotakos, D. B. (2026) · American Heart Journal · doi:10.1016/j.ahj.2026.107540
Natale, F., Loffredo, F. S., Pezzullo, E., Ciaramella, F., Golino, P., & Cimmino, G. (2026) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2026.07.002
Corrao, S., & Federici, M. (2026) · Acta Diabetologica · doi:10.1007/s00592-026-02748-8
Thanopoulou, A. C., Tentolouris, A., Vlachopoulos, C. V., Gastouniotis, I., Dima, I., Kirlaki, E., Anyfantakis, A., Foukarakis, E. G., Rogdakis, E., Stavrakis, S., et al. (2026) · Hellenic Journal of Cardiology · doi:10.1016/j.hjc.2026.07.004
Sani, E., Briani, F., Venturi, G., Bacchion, F., Balzano, S., Battocchio, M., D'Elia, K., Ferri, N., Frigo, G. M., Licchelli, L., et al. (2026) · Atherosclerosis Plus · doi:10.1016/j.athplu.2026.100624
Kakaletsis, N., Kosmidou, M., Sagris, D., Zafras, I., Papadimitriou, D., & Florentin, M. (2026) · Journal of Atherosclerosis Prevention and Treatment · doi:10.4103/aptj.aptj_25_26
Lit, V. F., Bak, J. C. G., van Bon, A. C., Serné, E. H., Sijstermans, K., Brouwer, C. B., Eland, I. A., Stouthart, P. J. H. M., van Bemmel, T., Groenwold, R. H. H., et al. (2026) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2026.113440
Castaneda, R., Tatit, C. P., Andrade, M. D. H., Faubion, S. S., & SHUFELT, C. L. (2026) · Maturitas · doi:10.1016/j.maturitas.2026.109058
Cicero, A. F. G., & Fogacci, F. (2026) · Nutrients · doi:10.3390/nu18142302
Dutta, N. (2026) · International Journal of Transgender Health · doi:10.1080/26895269.2026.2701924
The 2026 Guideline on the Management of Dyslipidemia supports future quality measure compliance
Willard, K.-E., & Hart, B. (2026) · Journal of clinical lipidology · doi:10.1016/j.jacl.2026.07.016
Khatami, S., Faghihi, M., Tavakoli, G., Szmit, S., & Yousefifard, M. (2026) · Cardiovascular Toxicology · doi:10.1007/s12012-026-10119-6
Österreichischer Lipidkonsensus 2026
Kronenberg, F., Höllerl, F., Brath, H., Rega‐Kaun, G., Greber‐Platzer, S., Weiser, C., Klein, D. P., Riesenhuber, N., Binder, C. J., Brix, J. M., et al. (2026) · Wiener klinische Wochenschrift · doi:10.1007/s00508-026-02760-6
Self-citationStępień, K., Ząbczyk, M., Natorska, J., Zalewski, J., Jawień, J., & Undas, A. (2026) · European Journal of Clinical Investigation · doi:10.1111/eci.70241
Lipoprotein(a) in Cardiovascular Disease Prevention: Current and Emerging Therapeutic Approaches
Osei, J., Bennett, J., Raval, O., Seo, G., Eisenberg, S. D., Nyenhuis, R., Gershon, G., Stresemann, S., Akkaya, S., Bhattacharya, A., et al. (2026) · Current Treatment Options in Cardiovascular Medicine · doi:10.1007/s11936-026-01149-y
Herbal Products for Cholesterol Lowering: A Narrative Overview
Bartkiewicz, P. A., Baran, W. P., Świątko, A., Jędrasek, T. W., Lachowska, E. M., Trzaskoma, A., & Chmiela, M. (2026) · Journal of Education Health and Sport · doi:10.12775/jehs.2026.94.72889
Escribano, M., Vallejo, P., Genua, I., Sardà, H., Chico, A. I., Tundidor, D., Cubero, J. M., Romero, J. M., Peypoch, O., Pérez, A., et al. (2026) · Endocrinología Diabetes y Nutrición · doi:10.1016/j.endinu.2026.501876
Statin therapy and outcomes in heart failure with mildly reduced ejection fraction
Schmitt, A., Behnes, M., Reinhardt, M., Abel, N., Goertz, M., Lau, F., Abumayyaleh, M., Akın, İ., & Schupp, T. (2026) · Hellenic Journal of Cardiology · doi:10.1016/j.hjc.2026.07.005
Lin, Y., Dai, J., Heianza, Y., Chien, K., & Qi, L. (2026) · Diabetes Obesity and Cardiometabolic CARE · doi:10.2337/doc26-0039
Mrabet, S., Saad, G., Cheikh, A. B., Awad, M. A., Halloul, I., Harbi, R., Eloillaf, M., Akkari, I., Hasni, Y., & Jazia, E. B. (2026) · Frontiers in Medicine · doi:10.3389/fmed.2026.1863576
Capturing Residual Inflammatory and Cardiometabolic Risk Beyond Low-Density Lipoprotein Cholesterol
Chan, K., & Gissler, M. C. (2026) · JACC. Cardiovascular imaging · doi:10.1016/j.jcmg.2026.06.006
Pauwels, R., Delpire, B., Hemelen, V. V., Peters, B., Robberechts, R., Paepe, J. D., Bekhuis, Y., Sinnaeve, P., Herbots, L., Gerche, A. L., et al. (2026) · American Journal of Preventive Cardiology · doi:10.1016/j.ajpc.2026.101755
LDL cholesterol lowering in primary prevention: Expanding eligibility without losing perspective
Cainzos‐Achirica, M., Shapiro, M. D., & Nasir, K. (2026) · American Journal of Preventive Cardiology · doi:10.1016/j.ajpc.2026.101757
Estratificação do risco cardiovascular na prevenção primária das doenças cardiovasculares
da Silva, M. D. C. R. G., Ribeiro, K. D. B., Rolim, N. R. F., Almeida, J. V. S., & de Araújo, S. T. (2026) · Revista fisio&terapia. · doi:10.69849/p5wxzh38
Pätzold, D., Vonbank, A., Clodi, M., Sourij, H., Hübner, D., Ebenbichler, C. F., Fagan, A., Farries, G., Hofstätter, E., Nitzlader, M., et al. (2026) · Journal of clinical lipidology · doi:10.1016/j.jacl.2026.07.025
Self-citationLaborda, C. G., Miguelena, P. R. D. G., Villa, C. R., Val, I. S., Sánchez, M. B., Hycka, J. M., & López, A. C. (2026) · Medicina Intensiva (English Edition) · doi:10.1016/j.medine.2026.502528
Ballantyne, C. M., Naderi, S., Taub, P. R., Rodríguez, F., Li, N., Bloedon, L. T., Herout, P. M., Cho, L., Lincoff, A. M., Nicholls, S. J., et al. (2026) · European Journal of Preventive Cardiology · doi:10.1093/eurjpc/zwag382
Self-citationRisk-Stratified Association of Lipoprotein(a) With Carotid Plaque Burden in Middle-Aged Adults
Κόλλιας, Α., Krystallaki, D., Komnianou, A., Τσαγανός, Θ., Stambolliu, E., Antonogiannaki, E.-C., Kyriakoulis, K. G., & Stergiou, G. S. (2026) · JACC Advances · doi:10.1016/j.jacadv.2026.103038
The Role of Triglycerides in the Development of Atherosclerosis
Cerebiejūtė, V., Girkantaitė, Ž., Rinkūnienė, E., Gimžauskaitė, S., & Badarienė, J. (2026) · Acta medica Lituanica · doi:10.15388/amed.2026.33.1.4
Cabello, M. I. E., Álvarez, P. A., Moraga, M. J. C., Cuenca, A. M. C., Cols-Sagarra, C., Hernández, Y. D., Ramos, P. G., Obaya, J. C., & Gil, F. A. (2026) · Medicina de Familia SEMERGEN · doi:10.1016/j.semerg.2026.102813
Treatment of severe hypertriglyceridemia: a new era dawns
Larouche, M., & Gaudet, D. (2026) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgag280
Morton, J. I., Kronenberg, F., Santos, R. D., Wiegman, A., Gutiérrez‐Ibarluzea, I., Kamstrup, P. R., Nicholls, S. J., Watts, G. F., & Ademi, Z. (2026) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2026.121850
Animati, F. M., Proietti, S., Auletta, F., Montone, R. A., Cappannoli, L., Fracassi, F., Gaspardone, A., & Burzotta, F. (2026) · Journal of Clinical Medicine · doi:10.3390/jcm15155897
Ghalib, N., Tyagi, M., Virani, S., Maki, K. C., Sperling, L. S., Banach, M., Nanna, M. G., Duell, P. B., Ray, K. K., Shapiro, M., et al. (2026) · European Journal of Preventive Cardiology · doi:10.1093/eurjpc/zwag392
Lipoprotein(a) and Cardiovascular Risk Gradient Across Coronary Artery Calcium Strata
Κόλλιας, Α., Krystallaki, D., & Τσαγανός, Θ. (2026) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2026.03.178
Barakat, H. E., Abougalambou, A. S., Maher, W., Nour, S. M., Abdelhalim, I. T., Binsaleh, A. Y., Belal, D. M. I., & Abougalambou, S. S. I. (2026) · Frontiers in Pharmacology · doi:10.3389/fphar.2026.1870914
Li, X., Zhang, Y., Zhang, H., Hu, C., & Li, X. (2026) · Revista de Neurología · doi:10.31083/rn53244
Kouched, N., Jmal, L., Zaouche, K., Dhieb, A., GUIDARA, R., & Jmal, A. (2026) · Journal of Clinical Pathology · doi:10.1136/jcp-2026-210814
Mwipatayi, B. P., Macaulay, R., Mwipatayi, D. L., Carnagarin, R., Varcoe, R. L., Wong, J., Golledge, J., Mori, T. A., Watts, G. F., & Schlaich, M. P. (2026) · Journal of Clinical Medicine · doi:10.3390/jcm15155949
Gencheva, I. I., & NUNEVA-DONCHEVA, R. (2026) · Diseases · doi:10.3390/diseases14080277
Effectiveness, safety, and treatment persistence of bempedoic acid in a Spanish real-world cohort
Jiménez, D. L., Martínez‐Hervás, S., Martínez, N. L., Jericó, C. R., Martínez-Soriano, M. J., Royuela, M., Franco‐Moreno, A., Rodríguez-Carnero, G., Varona, J. F., Molinero, A. M., et al. (2026) · Journal of clinical lipidology · doi:10.1016/j.jacl.2026.07.033
Nguyen, C., Ryali, R., Skaar, J. R., Chow, W., Robar, C., Kaufman, A., Li, W., & Shah, B. (2026) · Cardiology and Therapy · doi:10.1007/s40119-026-00459-3
Matsunaga, T., Nakatani, E., Sato, Y., Kaneda, H., Ohno, H., & Sugawara, A. (2026) · Journal of Health Population and Nutrition · doi:10.1186/s41043-026-01408-5
Bao, L., Li, Z.-F., Liu, X.-N., Yin, Z., Li, X., Lu, M.-Y., Zhang, W.-J., Luo, F., Xu, Y.-L., Li, J., et al. (2026) · Nutrition Metabolism and Cardiovascular Diseases · doi:10.1016/j.numecd.2026.104950
Lipoprotein(a) as a Cardiovascular Risk Factor: Clinical Significance and Therapeutic Perspectives
Miszczak, M., Piwowarczyk, P., Sobieszek, G., Dobrowolski, P., & Prejbisz, A. (2026) · Biomedicines · doi:10.3390/biomedicines14081743
Acute coronary syndrome: patient profile based on epidemiological and clinical characteristics
Ελευθεριάδου, Ε. Σ. (2026) · University of Thessaly Institutional Repository (University of Thessaly)
Lipoprotein apheresis: still needed in many patients, or soon a historical practice?
Schettler, V. J. J., Akgun, Y., Floege, J., & Zoccali, C. (2026) · Clinical Kidney Journal · doi:10.1093/ckj/sfag240
From Needle to Pill: Oral PCSK9 Inhibition Enters the Lipid-Lowering Armamentarium
Belančić, A., & Borovac, J. A. (2026) · Journal of Cardiovascular Pharmacology and Therapeutics · doi:10.1177/10742484261476920
Wang, B., & Li, D. (2026) · Lipids in Health and Disease · doi:10.1186/s12944-026-03023-z
Impact of Hypercholesterolemia on Pregnancy and Postpartum
Goldstein, A. K., Fisher, M. B., Trivedi, V., & Florio, K. L. (2026) · Obstetrics and Gynecology Clinics of North America · doi:10.1016/j.ogc.2026.06.003
Egalini, F., Riccio, E., Grasso, M., Nelva, A., & Geronimo, V. D. (2026) · Nutrients · doi:10.3390/nu18152538
Yu, X., Amone, F., Zaccaria, V., Minno, A. D., Daglia, M., Insolia, V., & Nobile, V. (2026) · Journal of Experimental Pharmacology · doi:10.2147/jep.s614937
Bajaj, A., McGuire, M., Shugg, S., Godin, R., & Underberg, J. A. (2026) · American Journal of Preventive Cardiology · doi:10.1016/j.ajpc.2026.101790
Amorim, M. A. D. O., Filho, J. M. K., & Rocha, V. Z. (2026) · Expert Review of Cardiovascular Therapy · doi:10.1080/14779072.2026.2718197
Capelli, I., Vetrano, D., Ribichini, D., Provenzano, M., Albertini, S., Berti, S., Sanfilippo, I., Vicennati, V., Pagotto, U., Manna, G. L., et al. (2026) · Journal of Nephrology · doi:10.1093/joneph/aajag105
Should LDL cholesterol targets be individualized according to bleeding risk?
Siniscalchi, C. (2026) · European Journal of Internal Medicine · doi:10.1016/j.ejim.2026.107139
Female-specific risk factors in cardiovascular risk prediction
Voskamp, L. W., de Boer, R. A., Dendale, P., & Ghossein‐Doha, C. (2026) · The Lancet Obstetrics Gynaecology & Women s Health · doi:10.1016/s3050-5038(26)00218-9
Ostrowska, M., Ratajczak, J. M., Ziółkowski, M., Adamski, P., Fabiszak, T., Grzelakowska, K., Laskowska, E., Niezgoda, P., Obońska, K., Umińska, J. M., et al. (2026) · International Journal of Cardiology Cardiovascular Risk and Prevention · doi:10.1016/j.ijcrp.2026.200697
Self-citationKang, H. H., Bae, Y., Kim, H., & Won, K. (2026) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2026.121879
Liu, S., Dai, J., Du, Y., & Hong, X. (2026) · Medicine · doi:10.1097/md.0000000000050245
Obicetrapib–ezetimibe combination therapy: a novel oral strategy for enhanced lipid lowering
Chitsazan, M., Chitsazan, M., & Cannon, C. P. (2026) · Cardiovascular Research · doi:10.1093/cvr/cvag138
Genedy, N., & Zouwail, S. (2026) · Journal of clinical lipidology · doi:10.1016/j.jacl.2026.07.022
Asero, C., Oliveri, C. V., Franzè, M. S., Basile, G. C., Catalano, A., & Cacciola, I. (2026) · Frontiers in Endocrinology · doi:10.3389/fendo.2026.1901793
Giamundo, D. M., Andò, G., Mamas, M. A., Pathak, A., Rosa, S. D., Bernardi, M., Figliozzi, S., Alasnag, M. A., Atar, D., Asher, E., et al. (2026) · Journal of Cardiovascular Development and Disease · doi:10.3390/jcdd13080393
Damianaki, A., Stambolliu, E., Iliakis, P., Theofilis, P., Vakka, A., Kalliakouda, E., Patsalis, P., Konstantinidis, D., & Petras, D. I. (2026) · Cardiovascular Drugs and Therapy · doi:10.1007/s10557-026-07934-y
Safety of lipid-lowering therapies: it is time for a “DOCebo” effect
D’Ardes, D. (2026) · Nutrition Metabolism and Cardiovascular Diseases · doi:10.1016/j.numecd.2026.104964
Wu, D., Yan, S., Li, X., Wang, J., Gao, N., Luo, M., Wang, X., Li, A., Zhang, R., Wu, L., et al. (2026) · Frontiers in Endocrinology · doi:10.3389/fendo.2026.1919240
Sarti, A., Sciaramenti, G., Camaiti, G., Cioci, P., Rizza, C., Tezze, R., Vocale, L. R., Hoxha, K., Maccaferri, I., Paparazzo, F., et al. (2026) · Journal of Clinical Medicine · doi:10.3390/jcm15166358
Κόλλιας, Α., Krystallaki, D., Antonogiannaki, E.-C., Komnianou, A., Τσαγανός, Θ., Kyriakoulis, K. G., Menti, A., & Stergiou, G. S. (2026) · Nutrition Metabolism and Cardiovascular Diseases · doi:10.1016/j.numecd.2026.104962
Kır, Y., Haymana, C., Torus, B., Güler, B. Y., Uflaz, B., Eroğlu, G., Gursoy, A., Boyraz, E., Akkan, T., Akın, Ş., et al. (2026) · Journal of Endocrinological Investigation · doi:10.1007/s40618-026-03024-w
Manicardi, M., Milić, J., Esposito, G., Menozzi, M., Mancini, G., Cuomo, G. L., Benassi, L., Delmonte, E., Ambrosio, S., Mussini, C., et al. (2026) · AIDS · doi:10.1097/qad.0000000000004594
Self-citationBeyond cholesterol: regression of carotid plaques in an adolescent-a case report
Zou, C., Pan, M.-Q., & Wang, M. (2026) · European Heart Journal - Case Reports · doi:10.1093/ehjcr/ytag603
Piriou, P., & Steg, P. G. (2026) · European Journal of Internal Medicine · doi:10.1016/j.ejim.2026.107157
Baik, M., Jeon, J., Yoo, J., & Kim, J. (2026) · Neurology · doi:10.1212/wnl.0000000000218491
Insights into Metabolically Healthy Obesity—A Narrative Review
Roșca, O.-R., & Tudoran, C. (2026) · Journal of Clinical Medicine · doi:10.3390/jcm15166446
Triệu, N. V., & Đông, N. X. (2026) · Tạp chí Y học Quân sự · doi:10.59459/1859-1655/jmm.1027
Beyond LDL-C: Modern Lipid Management for ASCVD Prevention in Primary Care
Carlson, A. M., Zayyad, Z. A., Driesenga, S., Boxley, P., Mishra, A., Uraizee, O., Ephrem, R., Zhang, R., Natsheh, Z., & Shroff, A. R. (2026) · Cardiology and Therapy · doi:10.1007/s40119-026-00473-5
D’Amuri, A., Cristini, I., Tebaldi, S., Speziali, A., Scopa, A., Pagani, M., Pellegrini, G., Santacà, K., Forti, A., Visigalli, C., et al. (2026) · Nutrition Metabolism and Cardiovascular Diseases · doi:10.1016/j.numecd.2026.104967
Shoji, S., Shrader, P., Freeman, N. L. B., Shah, N. P., Bittner, V., Wilcox, T., Doran, A. C., Wójcik, C., Jin, R., Jones, L. K., et al. (2026) · JACC Advances · doi:10.1016/j.jacadv.2026.103160
Neue Strategien der Lipidtherapie: Implikationen des ESC/EAS-Updates 2025
Schneider, T., & Laufs, U. (2026) · DMW - Deutsche Medizinische Wochenschrift · doi:10.1055/a-2676-2694
Self-citationWełnicki, M. T., Surma, S., Kapłon‐Cieślicka, A., & Janiszewski, M. (2026) · Cardiology Journal · doi:10.5603/cj.112385
Current Medical Therapy in Epicardial and Microvascular Disease: Evidence and Gaps
Angeli, F., Armillotta, M., Bergamaschi, L., & Pizzi, C. (2026) · Cardiology Clinics · doi:10.1016/j.ccl.2026.07.002
Viewpoint: Which Patient Is a VESALIUS-CV Patient? Rethinking Primary and Secondary Prevention
Mancini, G. B. J., & Hegele, R. A. (2026) · Canadian Journal of Cardiology · doi:10.1016/j.cjca.2026.08.010
Yu, Y., 常三帅, Shang, K., Jiao, Y., Li, Y., Tian, L., Song, G., & Yin, C. (2026) · Journal of Intensive Care Medicine · doi:10.1177/08850666261469110
Temporal Trends in the Use of Primary Prevention Medications at Stroke Admission
Burns, C., Kilkenny, M. F., Oliver, C., Purvis, T., Cadilhac, D. A.-M., Hill, K., Nelson, M. R., Kleinig, T., & Dalli, L. L. (2026) · Neuroepidemiology · doi:10.1159/ned/adwag013
Strandberg, T. E., Strandberg, A. Y., Pitkälä, K. H., & Mika Kivimaki, B. (2026) · European Journal of Preventive Cardiology · doi:10.1093/eurjpc/zwag429
Hypocholesterolemia in liver and cardiovascular disease: Friend or foe?
Flagiello, V., Barreby, E., Gentilucci, U. V., & Romeo, S. (2026) · Journal of Internal Medicine · doi:10.1111/joim.70142
Zhang, X., Niu, D., Li, Y., Wang, Y., Chen, R., & Xing, G. (2026) · Frontiers in Neurology · doi:10.3389/fneur.2026.1902614
2026 ESC Guidelines on cardiac rehabilitation
Bäck, M., Wilhelm, M., Marcin, T., Machado, F. V. C., Sandberg, A., Buccheri, S., Conde, A. C., Czapla, M., Rosa, S. D., Gibson, I., et al. (2026) · European Journal of Preventive Cardiology · doi:10.1093/eurjpc/zwag417 · Cited by 1
Self-citationSyed, A. B., Michalak, S., Potulapati, I., Vignarajah, A., & Shah, G. V. (2026) · Journal of Clinical Medicine · doi:10.3390/jcm15176640
Banach, M., Jaiswal, V., Ang, S. P., Ahuja, H., Khan, M. S., Qamar, A., Bielecka-Dabrowa, A. M., Slipczuk, L. N., Martin, S. S., & Crea, F. (2026) · European Heart Journal - Cardiovascular Pharmacotherapy · doi:10.1093/ehjcvp/pvag067
Andersen, A. S. V., Sødergren, S. T. F., Modin, D., Simonsen, J. Ø., Mohamed, A. A., Pareek, M., Spall, H. G. C. V., Gislason, G., Torp-Pedersen, C. T., & Biering‐Sørensen, T. (2026) · European Journal of Preventive Cardiology · doi:10.1093/eurjpc/zwag448
Wenzl, F. A., Wang, Y., Mass, V., Stæger, F. F., Siedliński, M., Satish, M., Linde, C. M., Bundgaard, H., Fuster, V., Guzik, T. J., et al. (2026) · European Heart Journal · doi:10.1093/eurheartj/ehag736
Coronary artery calcium and cardiovascular prevention
Jørgensen, M. D., Ravn, E. J., Øvrehus, K. A., Diederichsen, A. C. P., & Kumarathurai, P. (2026) · Ugeskrift for Læger · doi:10.61409/v12251058
Metadata
- Authors
- Mach, F., Koskinas, K. C., Roeters van Lennep, J. E., Tokgözoğlu, L., Badimon, L., Baigent, C., Benn, M., Binder, C. J., Catapano, A. L., De Backer, G. G., Delgado, V., Fabin, N., Ference, B. A., Graham, I. M., Landmesser, U., Laufs, U., Mihaylova, B., Nordestgaard, B. G., Richter, D. J., Sabatine, M. S., ESC/EAS Scientific Document Group, Mueller, C. E., Drexel, H., Abreu, A., Adamo, M., Aktaa, S., Asselbergs, F. W., Baldini, A., Boriani, G., Brida, M., Brodmann, M., Cenko, E., Dagres, N., Dopheide, J., Ebenbichler, C., Gandjbakhch, E., Gorog, D. A., Gouni-Berthold, I., Guasti, L., Heidecker, B., Ibanez, B., James, S., Juni, P., Kałużna-Oleksy, M., Krychtiuk, K. A., Lip, G. Y. H., Lorusso, R., Mahfoud, F., Metra, M., Moelgaard, I., Morais, J., Neubeck, L., Nissen, S. E., Osto, E., Parhofer, K. G., De Isla, L. P., Pesce, M., Petrulioniene, Z., Prescott, E., Rietzschel, E., Rocca, B., Rodriguez Palomares, J. F., Rossello, X., Sannino, A., Semb, A. G., Siller-Matula, J. M., Socrates, T., Tanner, F. C., Wojta, J., Zambon, A., Zeppenfeld, K., Laredj, N., Hayrapetyan, H., Speidl, W. S., Samadov, F., van de Borne, P., Kusljugic, Z., Postadzhiyan, A., Heracleous, H., Ostadal, P., Henriksen, F. L., Mohamed, M. S., Viigimaa, M., Juonala, M., Boccara, F., Chukhrukidze, A., Weingärtner, O., Marketou, M., Kiss, R. G., Sigurdsson, A. F., Maher, V., Henkin, Y., Nodari, S., Bekbossynova, M., Ibrahimi, P., Mirrakhimov, E., Jegere, S., Arnaout, S., Bheleel, O., Plisiene, J., Visser, L., Abela, M., Ivanov, V., Boskovic, A., Mbarek, N., Leening, M. J. G., Bosevski, M., Vesterbekkmo, E. K., Kubica, J., Ferreira, J., Pop, D., Stefanelli, U. M., Giga, V., Pella, D., Fras, Z., Fernandez-Olmo, R., Nilsson, L., Sudano, I., Marjeh, M. Y. B., Triki, F., Degertekin, M. M., Mitchenko, O., Banerjee, A., & Shek, A.
- Affiliations
- (Switzerland)
- (Netherlands)
- (Türkiye)
- (Spain)
- (United Kingdom)
- (Denmark)
- (Austria)
- (Italy)
- (Belgium)
- (Ireland)
- (Germany)
- (Greece)
- (United States of America)
- (Portugal)
- (Croatia)
- (France)
- (Sweden)
- (Poland)
- (Austria/Switzerland)
- (Italy/Saudi Arabia)
- (Lithuania)
- (Norway)
- Corresponding author
- Mach, François
- Koskinas, Konstantinos C
- ORCID
- Mach, François
- Koskinas, Konstantinos C
- Roeters van Lennep, Jeanine E
- Tokgözoğlu, Lale
- Badimon, Lina
- Baigent, Colin
- Benn, Marianne
- Binder, Christoph J
- Catapano, Alberico L
- De Backer, Guy G
- Delgado, Victoria
- Fabin, Natalia
- Graham, Ian M
- Landmesser, Ulf
- Laufs, Ulrich
- Mihaylova, Borislava
- Nordestgaard, Børge Grønne
- Richter, Dimitrios J
- Sabatine, Marc S
- Mueller, Christian Eugen
- Drexel, Heinz
- Abreu, Ana
- Adamo, Marianna
- Aktaa, Suleman
- Asselbergs, Folkert W
- Boriani, Giuseppe
- Brida, Margarita
- Brodmann, Marianne
- Cenko, Edina
- Dagres, Nikolaos
- Dopheide, Jörn
- Ebenbichler, Christoph
- Gandjbakhch, Estelle
- Gorog, Diana A
- Guasti, Luigina
- Heidecker, Bettina
- James, Stefan
- Krychtiuk, Konstantin A
- Lip, Gregory Y H
- Lorusso, Roberto
- Mahfoud, Felix
- Metra, Marco
- Neubeck, Lis
- Nissen, Steven E
- Osto, Elena
- Parhofer, Klaus G
- Pesce, Maurizio
- Prescott, Eva
- Rietzschel, Ernst
- Rocca, Bianca
- Sannino, Anna
- Semb, Anne Grete
- Siller-Matula, Jolanta M
- Socrates, Thenral
- Tanner, Felix C
- Wojta, Johann
- Zambon, Alberto
- Zeppenfeld, Katja
- Hayrapetyan, Hamlet
- Speidl, Walter Stefan
- Samadov, Fuad
- van de Borne, Philippe
- Postadzhiyan, Arman
- Henriksen, Finn Lund
- Juonala, Markus
- Boccara, Franck
- Chukhrukidze, Archil
- Weingärtner, Oliver
- Marketou, Maria
- Nodari, Savina
- Bekbossynova, Makhabbat
- Mirrakhimov, Erkin
- Bheleel, Osama
- Abela, Mark
- Ivanov, Victoria
- Leening, Maarten J G
- Bosevski, Marijan
- Vesterbekkmo, Elisabeth K
- Kubica, Jacek
- Ferreira, Jorge
- Pop, Dana
- Giga, Vojislav
- Pella, Daniel
- Sudano, Isabella
- Triki, Faten
- Mitchenko, Olena
- Banerjee, Amitava
- Shek, Aleksandr
- Venue
- European Heart Journal
- Publisher
- Oxford University Press (OUP)
- Published
- 2025-08-29
- Volume
- 46
- Issue
- 42
- Pages
- 4359-4378
- ISSN
- 0195-668X (ISSN-L)
- 1522-9645
- OpenAlex
- W4413804012
- Cited by
- 688
- References
- 136
- Citations by year
- 2026: 601 · 2025: 87
- FWCI
- 649.14
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- European Heart Journal (publishedVersion)
- PubMed (publishedVersion)
- EUR Research Repository (Erasmus University Rotterdam) (publishedVersion, other-oa)
- Ghent University Academic Bibliography (Ghent University) (submittedVersion)
- Archivio Istituzionale della Ricerca - Università Vita-Salute San Raffaele (submittedVersion, other-oa)
- Archivio istituzionale della ricerca (Alma Mater Studiorum Università di Bologna) (submittedVersion)
- UCL Discovery (University College London) (submittedVersion)
- IrInSubria (University of Insubria) (submittedVersion)
- Research at the University of Copenhagen (University of Copenhagen) (submittedVersion)
- Padua Research Archive (University of Padova) (submittedVersion, other-oa)
- Zurich Open Repository and Archive (University of Zurich) (submittedVersion)
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipoproteins and Cardiovascular Health
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
- Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Health Promotion and Cardiovascular Prevention
- Keywords
- dyslipidemia, dyslipidemia management, cardiovascular risk prediction, LDL-C lowering therapy, acute coronary syndrome, lipoprotein(a), hypertriglyceridemia, HIV infection, cancer patients, statins, dietary supplements, treatment goals, cardiovascular risk reduction, cardiovascular mortality, cardiovascular hospitalization, cardiovascular disease prevention
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
